Track the Straumann Holding AG stock price and the full directors' dealings record of the company, a listed issuer based in Switzerland. Shares trade on CH CH, under the authority of SIX SER. Operating in the Healthcare & Pharma sector, Straumann Holding AG has logged 95 reports. Market capitalisation: €17.2bn. The latest transaction was reported on 30 June 2026 (Sale). Among the most active insiders: Anonymous (Executive member of the board of directors / member of senior management). Every trade is accessible without an account.
Analysts rate Straumann Holding AG Buy (bullish), based on 18 analysts. Average price target: CHF 109.83.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
25 of 95 declarations
Straumann Holding AG is a leading global player in dental implantology and orthodontic solutions. Listed on the SIX Swiss Exchange (SMI/SPI) in Switzerland, the company offers investors a defensive healthcare profile with growth supported by innovation, demographic aging, and rising oral-care demand. Headquartered in Basel, Switzerland, Straumann was founded in 1954 and has evolved into an international reference in tooth replacement and aesthetic dentistry. ([straumann.com](https://www.straumann.com/us/en/dental-professionals/about/the-straumann-group.html?utm_source=openai)) The group operates across several complementary business lines: implantology, prosthetics, biomaterials, digital solutions, and orthodontics. Its portfolio includes the Straumann, Neodent, Medentika, Anthogyr, and ClearCorrect brands, along with technology partnerships and digital workflow tools. This broad offering allows the company to cover a significant part of the treatment chain, from implants to CAD/CAM restorations, guided surgery, intra-oral scanning, and clear aligners. ([straumann.com](https://www.straumann.com/group/en/home/about/contact-us/contact-our-brands.html?utm_source=openai)) From a competitive standpoint, Straumann stands out through strong scientific credibility, a broad global distribution network, and close relationships with dental professionals, laboratories, and dental service organizations. The group says its products, solutions, and services are available in more than 100 countries, giving it a highly diversified geographic footprint. Its strategy is built around clinical education, product innovation, manufacturing quality, and the gradual integration of digital technologies into treatment workflows. ([straumann.com](https://www.straumann.com/us/en/dental-professionals/about/the-straumann-group.html?utm_source=openai)) Recent developments point to continued operational momentum. The 2024 and 2025 disclosures highlight solid commercial trends, market-share gains, strategic execution improvements, and further progress in digital offerings. Straumann also continued to streamline its portfolio, including the divestment of DrSmile, in order to focus resources on its core businesses with the strongest conviction. Full-year 2025 results, published in early 2026, indicated continued organic growth and strategic progress despite a more volatile macroeconomic and geopolitical backdrop. ([straumann.com](https://www.straumann.com/group/en/discover/annualreport/2024.html?utm_source=openai)) For francophone investors, Straumann combines exposure to a structurally attractive dental healthcare market with strong brand leadership and innovation potential, while remaining sensitive to foreign exchange movements, discretionary demand in certain segments, and commercial execution in key geographies.